Search results for "Hazard"

showing 10 items of 1517 documents

Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mort…

2002

We evaluated a possible interaction between statins and inflammation in 1,246 patients with angiographically diagnosed coronary artery disease. Four different inflammatory markers were determined: high, sensitive C-reactive protein (hs-CRP) (p = 0.001), fibrinogen (p = 0.006), von Willebrand factor (p = 0.006), and leukocyte count (p = 0.03); these levels were significantly higher among the 88 patients who died of cardiac causes during follow-up (median 2.9 years) than among survivors. In a multivariate backward stepwise Cox regression mode, only hs-CRP was evaluated to be a significant predictor of death from coronary artery disease. This prediction was lost in statin-treated patients. Com…

Malemedicine.medical_specialtyTime FactorsStatinmedicine.drug_classCoronary Artery DiseaseCoronary AngiographyFibrinogenCoronary artery diseaseLeukocyte CountVon Willebrand factorPredictive Value of TestsRisk FactorsInternal medicinevon Willebrand FactormedicineHumansProspective StudiesRisk factorProspective cohort studyAgedProportional Hazards Modelsbiologybusiness.industryC-reactive proteinFibrinogenMiddle Agedmedicine.diseaseC-Reactive ProteinMultivariate Analysisbiology.proteinCardiologyFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessAcute-Phase ProteinsFollow-Up Studiesmedicine.drugLipoproteinThe American Journal of Cardiology
researchProduct

In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French regi…

2019

Summary Background Cancer and acute myocardial infarction (AMI) have important prognostic consequences. Treatment of some cancers may affect coronary artery disease, myocardial function and/or AMI management. Whether the early and long-term mortality of patients with AMI differ according to their history of cancer remains questionable. Aims To determine in-hospital outcomes and 5-year mortality following AMI according to patient history of cancer. Methods The FAST-MI registry is a nationwide French survey collecting data on characteristics, management and outcomes of 3670 consecutive patients admitted for AMI during October 2005. Results Overall, 246/3664 patients (6.7%) admitted for an AMI…

Malemedicine.medical_specialtyTime Factors[SDV]Life Sciences [q-bio]Infarctus du myocardeAcute myocardial infarction030204 cardiovascular system & hematologyMortalitéRisk AssessmentCoronary artery disease03 medical and health sciences0302 clinical medicineRisk FactorsNeoplasmsInternal medicineMortalité hospitalière.medicineHumansMedical historyHospital MortalityProspective StudiesRegistries030212 general & internal medicineMyocardial infarctioncardiovascular diseasesRisk factorMortalityNon-ST Elevated Myocardial InfarctionAgedCancerAged 80 and overbusiness.industryST elevationHazard ratioGeneral MedicineOdds ratioMiddle Agedmedicine.disease3. Good healthHospitalization[SDV] Life Sciences [q-bio]In-hospital mortalityTreatment OutcomeCohortST Elevation Myocardial InfarctionFemaleFranceCardiology and Cardiovascular Medicinebusiness
researchProduct

Mortality after cardioverter-defibrillator replacement: Results of the DECODE survival score index

2020

Background Device replacement is the ideal time to reassess health care goals regarding continuing implantable cardioverter-defibrillator (ICD) therapy. Only few data are available on the decision making at this time. Objectives The goals of this study were to identify factors associated with poor prognosis at the time of ICD replacement and to develop a prognostic index able to stratify those patients at risk of dying early. Methods DEtect long-term COmplications after implantable cardioverter-DEfibrillator replacement (DECODE) was a prospective, single-arm, multicenter cohort study aimed at estimating long-term complications in a large population of patients who underwent ICD/cardiac resy…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulationReplacementCardiac resynchronization therapy030204 cardiovascular system & hematologyPrognostic indexImplantable cardioverter-defibrillatorNOElectrocardiography03 medical and health sciences0302 clinical medicineInterquartile rangePhysiology (medical)Internal medicinemedicineHumansProspective Studies030212 general & internal medicineeducationShared decision makingAgedOutcomeAged 80 and overHeart Failureeducation.field_of_studyIschemic cardiomyopathybusiness.industryProportional hazards modelMiddle AgedImplantable cardioverter-defibrillatorDefibrillators ImplantableSurvival RateDeath Sudden CardiacItalyFemaleCardiology and Cardiovascular MedicinebusinessDecision Making SharedBody mass indexFollow-Up StudiesCohort study
researchProduct

Prognostic Value of Microvascular Obstruction and Infarct Size, as Measured by CMR in STEMI Patients

2014

The aim of this study was to evaluate the value of microvascular obstruction (MO) and infarct size as a percentage of left ventricular mass (15%LV), as measured by contrast-enhanced cardiac magnetic resonance, in predicting major cardiovascular adverse events (MACE) at 2 years in patients with ST-segment elevation myocardial infarction reperfused by primary percutaneous coronary intervention. Individual data from 1,025 patients were entered into the pooled analysis. MO was associated with the occurrence of MACE, defined as a composite of cardiac death, congestive heart failure, and myocardial re-infarction (adjusted hazard ratio: 3.74; 95% confidence interval: 2.21 to 6.34). IS% LV >= 25% w…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentmicrovascular obstructionHeart VentriclesMyocardial Infarction[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineRisk Assessmentcardiac magnetic resonance[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicinePercutaneous Coronary InterventionPredictive Value of TestsRecurrenceRisk FactorsInternal medicineCoronary CirculationMedicineinfarct sizeHumansRadiology Nuclear Medicine and imagingMyocardial infarctioncardiovascular diseasesAdverse effectComputingMilieux_MISCELLANEOUSAgedHeart Failurebusiness.industryMicrocirculationMyocardiumHazard ratioPercutaneous coronary interventionMiddle Agedmedicine.diseaseMagnetic Resonance ImagingConfidence intervalTreatment OutcomeRadiology Nuclear Medicine and imagingHeart failureNo reflow phenomenonCardiologyNo-Reflow PhenomenonFemaleprognosisCardiology and Cardiovascular MedicinebusinessMaceJACC. Cardiovascular imaging
researchProduct

Dietary fat intake and risk of cardiovascular disease and all-cause mortality in a population at high risk of cardiovascular disease.

2015

Background Dietary fat quality and fat replacement are more important for cardiovascular disease (CVD) prevention than is total dietary fat intake. Objective The aim was to evaluate the association between total fat intake and fat subtypes with the risk of CVD (myocardial infarction, stroke, or death from cardiovascular causes) and cardiovascular and all-cause death. We also examined the hypothetical effect of the isocaloric substitution of one macronutrient for another. Design We prospectively studied 7038 participants at high CVD risk from the PREvencion con DIeta MEDiterranea (PREDIMED) study. The trial was conducted from 2003 to 2010, but the present analysis was based on an expanded fo…

Malemedicine.medical_specialtyTrans fatMediterranean dietSaturated fatPopulationMedicine (miscellaneous)Lower riskDiet MediterraneanGastroenterologyCohort StudiesDietary Fats UnsaturatedRisk FactorsInternal medicineFood PreservedMedicineHumansMyocardial infarctionProspective StudiesMortalityeducationAgedProportional Hazards Modelschemistry.chemical_classificationAged 80 and overeducation.field_of_studyNutrition and Dieteticsbusiness.industryIncidencefood and beveragesTrans Fatty Acidsmedicine.diseaseDietary FatsEndocrinologychemistryCardiovascular DiseasesSpainElder Nutritional Physiological PhenomenaSaturated fatty acidFatty Acids UnsaturatedFast Foodslipids (amino acids peptides and proteins)FemalebusinessPolyunsaturated fatty acidFollow-Up StudiesThe American journal of clinical nutrition
researchProduct

The relation between the incidence of hypernatremia and mortality in patients with severe traumatic brain injury

2009

Introduction The study was aimed at verifying whether the occurrence of hypernatremia during the intensive care unit (ICU) stay increases the risk of death in patients with severe traumatic brain injury (TBI). We performed a retrospective study on a prospectively collected database including all patients consecutively admitted over a 3-year period with a diagnosis of TBI (post-resuscitation Glasgow Coma Score ≤ 8) to a general/neurotrauma ICU of a university hospital, providing critical care services in a catchment area of about 1,200,000 inhabitants. Methods Demographic, clinical, and ICU laboratory data were prospectively collected; serum sodium was assessed an average of three times per …

Malemedicine.medical_specialtyTraumatic brain injuryCritical Care and Intensive Care MedicineSeverity of Illness Indexlaw.inventionHospitals UniversitylawSeverity of illnessmedicineHumansDeamino Arginine VasopressinIntensive care medicineProportional Hazards ModelsRetrospective StudiesSaline Solution HypertonicHypernatremiabusiness.industryIncidenceResearchIncidence (epidemiology)Glasgow Coma ScaleRetrospective cohort studyMiddle Agedmedicine.diseaseIntensive care unitHypertonic salineIntensive Care UnitsBrain InjuriesEmergency medicineCommentaryFemaleHypernatremiaIntracranial HypertensionbusinessCritical Care
researchProduct

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

2006

BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary…

Malemedicine.medical_specialtyUrologyKaplan-Meier EstimateType 2 diabetesPharmacologyWeight GainRosiglitazoneGlibenclamidechemistry.chemical_compoundDouble-Blind MethodDiabetes mellitusGlyburidemedicineHumansHypoglycemic AgentsProportional Hazards ModelsGlycemicGlycated HemoglobinGlycemic efficacyWaist-Hip Ratiobusiness.industryCholesterol LDLGeneral MedicineMiddle Agedmedicine.diseaseMetforminMetforminTreatment OutcomeDiabetes Mellitus Type 2chemistryCardiovascular DiseasesFemaleThiazolidinedionesGlycated hemoglobinbusinessRosiglitazonemedicine.drugNew England Journal of Medicine
researchProduct

Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.

2005

OBJECTIVES To report the long-term follow-up of patients with locally advanced bladder cancer treated with either adjuvant combined chemotherapy with methotrexate, vinblastine, doxorubicin/epirubicin, and cisplatin (MVAC/MVEC) or no additional treatment after radical cystectomy, to examine various survival endpoints and factors associated with long-term survival. PATIENTS AND METHODS Between May 1987 and December 1990, 49 patients undergoing radical cystectomy for locally advanced bladder cancer were randomized to observation only or adjuvant systemic chemotherapy with three cycles of MVAC/MVEC (methotrexate 30 mg/m2 on day 1, 15 and 22; vinblastine 3 mg/m2 on day 2, 15 and 22; doxorubicin …

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyVinblastineDisease-Free SurvivalCystectomyAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedEpirubicinChemotherapyBladder cancerbusiness.industryHazard ratioCombination chemotherapyMiddle Agedmedicine.diseaseInterim analysisCombined Modality TherapyVinblastineSurgeryMethotrexateTreatment OutcomeUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinLymphatic MetastasisFemaleCisplatinNeoplasm Recurrence Localbusinessmedicine.drugEpirubicinFollow-Up StudiesBJU international
researchProduct

Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Fai…

2019

Importance Short-term infusions of single vasodilators, usually given in a fixed dose, have not improved outcomes in patients with acute heart failure (AHF). Objective To evaluate the effect of a strategy that emphasized early intensive and sustained vasodilation using individualized up-titrated doses of established vasodilators in patients with AHF. Design, Setting, and Participants Randomized, open-label blinded-end-point trial enrolling 788 patients hospitalized for AHF with dyspnea, increased plasma concentrations of natriuretic peptides, systolic blood pressure of at least 100 mm Hg, and plan for treatment in a general ward in 10 tertiary and secondary hospitals in Switzerland, Bulgari…

Malemedicine.medical_specialtyVasodilator AgentsComorbidityPatient Readmission01 natural sciencesDrug Administration Schedulelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawCause of DeathInternal medicineClinical endpointHumansMedicine030212 general & internal medicine0101 mathematicsAdverse effectAgedCause of deathAged 80 and overHeart Failurebusiness.industry010102 general mathematicsHazard ratioGeneral Medicinemedicine.diseaseHospitalizationBlood pressureHeart failureAcute DiseaseFemalebusinessSacubitril ValsartanJAMA
researchProduct

Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national…

2021

Abstract Aims Vitamin K antagonists (VKAs) are effective drugs reducing the risk for stroke in atrial fibrillation (AF), but the benefits derived from such therapy depend on the international normalized ratio (INR) maintenance in a narrow therapeutic range. Here, we aimed to determine independent variables driving poor anticoagulation control [defined as a time in therapeutic range (TTR) <65%] in a ‘real world’ national cohort of AF patients. Methods and results The SULTAN registry is a multicentre, prospective study, involving patients with non-valvular AF from 72 cardiology units expert in AF in Spain. At inclusion, all patients naïve for oral anticoagulation were started with VKAs…

Malemedicine.medical_specialtyVitamin K030204 cardiovascular system & hematologyAmiodaroneCoronary artery disease03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineAtrial FibrillationHumansMedicineInternational Normalized RatioProspective StudiesRegistries030212 general & internal medicineProspective cohort studyStrokeAgedAged 80 and overbusiness.industryProportional hazards modelAnticoagulantsAtrial fibrillationOdds ratioMiddle Agedmedicine.diseaseConfidence intervalStrokeFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEP Europace
researchProduct